The survival gap no one should accept

Every year, an estimated 400,000 children develop cancer. Unlike many adult cancers, childhood cancer is generally not preventable, so the most powerful tool doctors have is catching it early and treating it properly. But a child diagnosed in a wealthy country faces a very different future than one diagnosed in a poor one. According to the World Health Organization, more than 80 percent of children with cancer in high-income countries are cured, compared with fewer than 30 percent in many low- and middle-income countries. The medicines exist. Most are cheap, long-established generics. They simply do not reach the children who need them.

The WHO wants to fix the supply chain rather than wait for new drugs. On September 15, 2026, the agency published a new market-shaping strategy for childhood cancer medicines, a five-year roadmap that examines why essential medicines keep running out and sets out ten coordinated interventions to strengthen supply, improve demand forecasting, support faster regulatory approval, expand quality-assured products, make procurement more efficient, promote sustainable financing, and create room for innovation. The strategy draws on the experience of the Global Platform for Access to Childhood Cancer Medicines, which WHO set up together with St. Jude Children's Research Hospital, working with UNICEF and the PAHO Strategic Fund.

Why the medicines never arrive

Getting the drugs to hospitals turns out to be an economics problem. Supply of essential childhood cancer medicines is unreliable and depends on a small number of manufacturers, particularly for products that meet international quality standards. Low- and middle-income countries tend to order in small amounts, which makes suppliers treat the demand as low priority and pushes prices up. Approvals move slowly, so a medicine can take years to become available in some places. And because childhood cancer affects fewer people than adult cancers, there is little commercial incentive to develop formulations designed for children in low-resource settings.

The shortages are not abstract. In East Africa, hospitals report frequent stockouts of essential chemotherapy agents, with 32 to 49 percent of critical medicines such as methotrexate and etoposide affected. Money breaks treatment too: in some settings, more than 70 percent of children being treated for leukaemia stop or never complete their treatment for financial reasons. Lower survival in poorer countries also comes from late diagnosis, inaccurate diagnosis, limited access to the right therapy, treatment abandonment, deaths from treatment-related toxicity, and relapses that could have been avoided. "No child should be denied a chance of survival because the medicines they need are unavailable, unaffordable, or out of reach," said Dr Carlos Rodriguez-Galindo, executive vice president of St. Jude Children's Research Hospital.

What the ten-point plan actually does

Instead of negotiating drug by drug, the WHO plan tries to repair the whole market. The ten interventions include working more closely with medicine companies, increasing the number of reliable suppliers, speeding up medicine approval, improving planning and purchasing, supporting research, improving price transparency, folding these medicines into national health benefit packages, and encouraging new treatments. "Rather than focusing only on individual products or prices, market shaping interventions aim to strengthen overall market health by improving the conditions required for sustainable access," the report states. Voluntary licensing plays a part as well: for medicines still protected by patents, the Global Platform plans to negotiate agreements that let selected quality-assured manufacturers produce and supply them in low- and middle-income countries under agreed conditions, adding competition, lowering prices, and cutting delays.

There is already evidence the approach can work. In 2024, Nepal declared free treatment for children with cancer at public health facilities, showing how national policy can remove the cost barrier. "Where the price is more friendly, there are plenty of suppliers; that's sort of the goal we're trying to reach," said Rongrong Liu, a program manager with St. Jude's global operations. Alessio Mola, a pharmacist at WHO, pointed to the logistics behind the shortages: "At the beginning, we have focused only on clinical forecast, but in reality there are a lot of logistical parameters that we need to consider." Dr Kennedy Lishimpi, permanent secretary for technical services at Zambia's Ministry of Health, said the strategy needs broad cooperation: "Persistent market challenges continue to affect access for children, and it is critical that we continue to work together to enhance the reliability and affordability of childhood cancer medicines."

The report, released during Childhood Cancer Awareness Month and reported by the Inter Press Service's UN bureau, ends on a plain point. Most types of childhood cancer can be cured with generic medicines, surgery, and radiotherapy that medicine has had for decades. The medical world already has the cures; the problem is getting them onto pharmacy shelves in every country. The full roadmap is published through the WHO website, which describes the strategy for building a healthier market through 2030.